|
| Jinqi Jiangtang tablets improve islet function in the treatment of type 2 diabetes mellitus: a systematic review |
| Hits 320 Download times 419 Received:October 09, 2023 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2024.02.09 |
| Key Words
Jinqi Jiangtang tablets;type 2 diabetes mellitus;insulin resistance;systematic review;RCT |
| Author Name | Affiliation | E-mail | | ZHU Zheng | School of Acupuncture and Massage, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZOU Jiahan | Binhai New Area Hospital of Traditional Chinese Medicine, Tianjin, Tianjin 300450, China | | | JIN Xinyao | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHAO Xia | Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050000, China | | | WANG Keyi | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHANG Yazi | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | YANG Fengwen | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | 13682027022@163.com |
|
| Abstract
|
| [Objective] To evaluate the efficacy and safety of Jinqi Jiangtang tablets for improving islet function in the treatment of type 2 diabetes mellitus. [Methods] The Chinese full-text Journal Database(CNKI),WanFang Data,and Chinese Biomedical Literature Database(SinoMed) were searched by computer,and the English database was searched by PubMed,Embase,and Cochrane library to search for Jinqi Jiangtang tablets in the treatment of type 2 diabetes from inception to June 2023. Randomized controlled trials(RCTS) reporting insulin sensitivity or insulin resistance index. Literature screening and data extraction were carried out independently by two researchers,and the quality of included studies was evaluated using bias risk assessment tools recommended in the Cochrane manual. RevMan 5.3.0 software was used for statistical analysis. [Results] Sixteen RCTS were included,with a total of 1306 patients. The main outcome indicators were as follows:In terms of reducing insulin resistance(HOMA-IR),Jinqi Jiangtang tablets combined with insulin secretagogues was superior to insulin secretagogues alone,and the difference between groups was statistically significant[MD=-0.69,95%CI(-1.04,-0.35)]. Jinqi Jiangtang tablets combined with thiazolidinediones(TZDs) were superior to TZDs alone,and the difference between groups was statistically significant[MD=-0.86,95%CI(-1.06,-0.66)]. In terms of improving islet β function(HOMA-IS),Jinqi Jiangtang tablets combined with TZDs was superior to TZDs alone,and the difference between groups was statistically significant[MD=-0.61,95%CI(-1.99,-0.02)]. In terms of increasing insulin sensitivity index(Sen,IAI,ISI),Jinqi Jietong tablets combined with metformin was superior to metformin alone,and the difference between groups was statistically significant[MD=0.45,95%CI(0.19,0.71)]. Jinqi Jiangtang tablets combined with gliclazide was superior to Gliclazide alone,and the difference between groups was statistically significant[MD=2.00,95%CI(1.28,2.72)]. Jinqi Jiangtang tablets combined with insulin secretagogues were superior to insulin secretagogues alone,and the difference was statistically significant[MD=0.97,95%CI(0.75,1.20)]. [Conclusion] Current evidence shows that Jinqi Jiangtang tablets combined with insulin secretagogues can improve HOMA-IR,increase insulin sensitivity and reduce the level of glycosylated hemoglobin while synergically reducing blood glucose. Jinqi Jiangtang tablets and TZDs,which increase insulin sensitivity,have synergistic effects on improving insulin resistance,increasing islet function,lowering blood glucose,improving fasting insulin and 2 h postprandial insulin. The combination of Jinqi Jiangtang tablets and Western medicine did not increase the occurrence of adverse reactions. Due to the low quality of the included studies,the conclusions need to be validated by high-quality randomized controlled trials. |
|
|
|
|
|
